Senores Pharmaceuticals Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sg5ifezvf2cc0u05ts3t0hqk.pdf

Key Takeaways


CDMO & Regulated Market Growth

Swapnil Shah: "I personally don't know in our size any company has that kind of capability to offer to our CDMO partners. So, I think that mixture is unique, that mixture is different and that will continue to leverage upon it."

Emerging Markets Turnaround

Sanjay Majmudar: "I think it's a little premature, but as Swapnil explained, when we acquired this business and then we have started transforming it, I think an optimum targeted level of EBITDA would be much higher, but we will speak as we go forward. But our internal target at the optimum level is at least 15% to 18%."

Margin Structure & Profitability

Swapnil Shah: "Our dependency on each product revenue stream is not more than 2% to 3%. So, even if that one product can give me a lot of competition, my revenue drops from 3% to 1.5% or maybe 2%. In overall scheme of things you look at it, my revenue is dropped only 1% from a competition..."

Product Portfolio & Competitive Position

Sanjay Majmudar: "We generally identify products which are relatively niche, underpenetrated. We have a very different philosophy. And then these are the products we generally large, big pharmas are not interested. But since they want it as a part of their pipeline, that is when we fit in very nicely. We don't compete with them. Rather, they are all our partners."

Capacity Expansion & Backward Integration


Guidance & Commitments

CommitmentSpecificsTimeline
CDMO product launches15-17 CDMO/CMO products to commercializeQ4 FY25
FY25 revenueINR 410-440 crores (+/-5%)FY25 full year
FY26 revenueINR 670-700 crores (50-60%+ growth)FY26 full year
FY26 PATNearly double vs. FY25FY26 full year
Emerging market EBITDAImprove to high single digitsFY26
Emerging market EBITDAReach higher teensFY26-27 to FY27-28
US plant utilizationInch up to 60-65%FY26
API facility commencementRegulated market API facility to startCurrent quarter (Q4 FY25)
Injectables CAPEXCAPEX spending to begin; completion in 18-24 monthsStarting Q1 FY26
Product launches5 products to launchQ4 FY25

Key Metrics

MetricQ3 FY25
Consolidated revenue₹906 cr, +35.2% YoY
9M FY25 consolidated revenue₹288 cr, +157% YoY from ₹112 cr in 9M FY24
Regulated markets revenue₹70 cr, +3% YoY
CDMO business growth68% YoY
Emerging markets revenue₹26 cr, +289% YoY; Q3 FY24 included Ratnatris for only 17 days post-acquisition
9M FY25 revenue mix64% regulated markets, 30% emerging markets, balance API and injectables
EBITDA₹29 cr, +92% YoY from ₹15 cr in Q3 FY24
EBITDA margin27%, up from 19% in Q3 FY24, an increase of ~810 bps
Regulated business EBITDA margin~40% in Q3 and YTD
Emerging markets EBITDA margin1% in Q3, 1.4% in 9M FY25
PAT after minority interest₹17 cr, +142% YoY from ₹7 cr in Q3 FY24
PAT margin16%, up from 9% in Q3 FY24, an increase of 710 bps
CDMO revenue as % of total revenue~11% in Q3, ~12-13% YTD
CDMO as % of regulated markets revenue~19% in Q3, ~24% in 9M FY25
Own products commercialized in regulated markets22 products; 5 more expected to launch in Q4 FY25
Approved ANDAs24 as of call date; 5 new approvals received in the quarter
Pipeline products (regulated markets)51 products; 28 have CGT opportunity
CDMO/CMO commercial products21 products; 69 in pipeline; 15-17 expected to commercialize in Q4 FY25
Emerging markets registered products267 products; 62 added in the quarter
Emerging markets products under registration537 products; 131 new filings planned
US plant utilization~50% currently; capacity augmented ~5x vs DRHP; expected to reach 60-65% in FY26
India plant utilization~60-65%, possibly 65-70%
FY25 full-year revenue expectation₹410 cr to ₹440 cr (+/-5%)
FY26 revenue expectation₹670 cr to ₹700 cr
FY26 CDMO/CMO revenue expectation$25 mn to $30 mn
FY25 full-year PAT expectation₹55 cr to ₹60 cr
FY26 CAPEXMore than ₹200 cr firmly on the ground
Top 5 customers share of own-product revenue~65%
Revenue dependency per own-productNot more than 2% to 3% per product